57 results about "Mumpsvax" patented technology

The present invention provides pyrimidinyl compounds of formula (I) and pharmaceutically acceptable salts thereof. These compounds may be used for the inhibition of influenza. In particular, the compounds of the invention may be used for the treatment or prophylaxis of influenza A, most particularly H1N1 or H5N1 influenza. The compounds of the invention can also be used for the treatment or prophylaxis of a disease caused by Vibrio cholerae, Clostridium perfringens, Streptococcus pneumoniae, Arthrobacter sialophilus, an orthomyxovirus, a paramyxovirus, a parainfluenza virus, mumps virus, Newcastle disease virus, fowl plague virus or Sendai virus.

The present invention relates to a novel pharmaceutical composition, specifically a novel pharmaceutical composition prepared by combining Folium Folium Folium and Houttuynia cordata and extracting active ingredients. The raw material medicine includes raw medicinal materials Folium Folium and Houttuynia cordata, wherein the raw medicinal material Houttuynia cordata is 1-1000 parts by weight, and the weight of Folium folium is 0.1-10 times that of Houttuynia cordata. When preparing the composition, the volatile oil in Houttuynia cordata is extracted first, the residue is mixed with Daqingye and then decocted, the concentrated solution is treated with a clarifying agent, and the Daqingye and Houttuynia are obtained through alcohol precipitation, water precipitation and filtration. The residue extract solution is mixed with the volatile oil and the extract solution, and various dosage forms of the pharmaceutical composition are obtained through post-processing. The pharmaceutical composition can be used for treating viral influenza, upper respiratory tract infection, mumps, pneumonia and other diseases.

The present invention relates to a hybridoma cell strain and a monoclonal antibody secreted thereof, the monoclonal antibody can specifically bind to human IgM and can be used for in vitro detection of the human IgM, and is particularly suitable for early diagnosis of mumps virus infection. The invention also relates to a kit comprising the hybridoma cell strain or the monoclonal antibody.

The invention discloses a medicine for treating tuberculosis of cervical lymph nodes, cyclomastopathy and mumps. The medicine is prepared by using the following raw materials by weight part: 4-5 parts of Chinese alangium leaves, 5-8 parts of omoto nipponlily roots, 8-10 parts of rumex madaio, 4-5 parts of Paris rhizomes, 8-10 parts of pokeberry roots, 4-5 parts of radix semiaquilegiae, 8-10 parts of dysosma versipellis and 3-4 parts of toads. A preparation method for the medicine provided by the invention comprises the following steps: weighting all the raw materials by weight part, washing the raw materials and then drying at the temperature below 35 DEG C; milling the raw materials into fine powder and screening by using a 100 mesh sieve; adding 60%-70% alcohol into the powder, wherein the weight of the alcohol is 3-4 times of the total weight of the powder; mixing and soaking for 5-7 days; removing the alcohol; and adding a suitable amount of honey and preparing into paste for externally applying. The medicine provided by the invention has the advantages that only few medicines are externally applied; the pains of a patient caused by taking medicines, injection and surgery are avoided; the application scope is wide; and the medicine is easily absorbed, quickly becomes effective, is high in cure rate, is low in cost and is free from side effect.